Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.
Primary hyperoxaluria type 1 (PH1) is a rare, progressive, inherited metabolic stone disease that is potentially life-threatening, and often presents with kidney stones.1-3
Primary hyperoxaluria (PH) is a group of autosomal-recessive metabolic stone diseases resulting from defects in different enzymes involved in glyoxylate metabolism that lead to an overproduction of oxalate in the liver.2,3 There are 3 types of PH: PH1, PH2, and PH3, each of which is caused by a defect in a different enzyme.3
PH1 often presents with kidney stones and is caused by autosomal recessive mutations in the AGXT gene, which impairs the function of the liver-specific enzyme alanine:glyoxylate aminotransferase (AGT).1,3 Normally, AGT processes glyoxylate, which is generated by another liver enzyme, glycolate oxidase (GO).2,3
70%-80% of PH cases are PH1. Even so, PH1 is a rare disease, affecting an estimated 1 to 3 cases per million population, and incidence rate of 1 case per 120,000 live births per year in Europe, with higher prevalence in the Middle East and North Africa region.1,3,7
One of the most devastating aspects of PH1 is that it causes a progressive decline in kidney function, culminating in end-stage kidney disease (ESKD).1,3,6 Moreover, there is the potential risk of systemic oxalosis.3
Management approaches may lessen damage by reducing stone formation and kidney deposition of calcium oxalate crystals; this underscores the importance of early diagnosis and intervention.3,7
PH1 leads to progressive decline in kidney function.2
Liver oxalate overproduction may lead to inflammation and progressive kidney function decline following calcium oxalate crystal formation.9 Continuous oxalate overproduction may lead to irreversible damage in the kidneys and other organs.9
PH1 advances at variable rates, progressing to ESKD.2 When the kidneys are unable to excrete oxalate effectively due to toxicity from calcium oxalate crystal deposition, systemic oxalosis—the widespread tissue deposition of calcium oxalate—can occur.9 Complications from systemic oxalosis can be fatal.2
In some instances, kidney function can decline after a single incident of dehydration due to acute illness or intense physical activity.10–13 This can occur even in patients with previously stable disease.9,11
PH1 is a genetic disease caused by mutations in the AGXT gene that renders the liver enzyme AGT dysfunctional.3
Normally, AGT processes glyoxylate, which is generated by another liver enzyme, GO.2,3 In PH1, a defect in AGT means glyoxylate is instead converted to oxalate.2 Oxalate cannot be metabolised and is typically excreted by the kidneys at normal levels.3 When overproduced as it is in PH1, oxalate can wreak progressive, irreversible damage.2 Oxalate combines with calcium, creating calcium oxalate crystals.2 These crystals attach to kidney tissues, where they can aggregate to form kidney stones or lead to nephrocalcinosis.2,9 As calcium oxalate accumulates, kidney excretion is impaired, and crystals deposit throughout the body.9
Kim Hollander
References: 1. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 2. Milliner DS, Harris PC, Cogal AG, Lieske JC. https://www.ncbi.nlm.nih.gov/books/NBK1283/. Updated November 30, 2017. Accessed October 2023. 3. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 4. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736. 5. Ben-Shalom E, Frishberg Y. Pediatr Nephrol. 2015;30(10):1781-1791. 6. Raju DL, Cantarovich M, Brisson ML, Tchervenkov J, Lipman ML. Am J Kidney Dis. 2008;51(1):e1-e5. 7. Bhasin B, Ürekli HM, Atta MG. World J Nephrol. 2015;4(2):235-244. 8. Hoppe B, Beck BB, Milliner DS. Kidney Int. 2009;75(12):1264-1271. 9. Leumann E, Hoppe B. J Am Soc Nephrol. 2001;12(9):1986-1993. 10. El-Reshaid K, Al-Bader D, Madda JP. Saudi J Kidney Dis Transpl. 2016;27(3):606-609. 11. Cochat P. Kidney Int. 1999;55(6):2533-2547. 12. Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Int J Nephrol. 2011;2011:864580. 13. Tintillier M, Pochet JM, Cosyns JP, Delgrange E, Donckier J. Clin Nephrol. 2004;62(2):155-157.
PH1-CEMEA-00126 | November 2023
ThinkPH1 is a trademark of Alnylam Pharmaceuticals, Inc.
©2023 Developed and produced by Alnylam Switzerland GmbH. All rights reserved.
PH1-CEMEA-00124
November 2023
Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for Healthcare Professionals in Europe, Middle East and Africa. For disease awareness purposes only.